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Summary: Allergic rhinitis is commonly found in Kashmir. Prophylactic Fexofenadine shows more promising 
activity with mild side effects at proper dosage schedule. 10 cases of Allergic Rhinitis were studied during a 
period from Jan 2013 to July 2015.Clinical symptomatology of Allergic rhinitis are described as recurrent 
,episodic  profuse mucoid nasal discharge, excessive sneezing and nasal obstruction. The associated symptoms 
being itching and burning sensation of conjunctiva, nasal mucosa and Oropharynx and the aggravation of the 
symptoms coincident with the pollination. The prophylactic treatment with Fexofenadine 120 mg once daily for 
3 weeks with 1 week drug wash-out interval in a month has proven very effective in preventing the acute attack 
of allergic rhinitis. The drug has been tried for such a prolonged time and is virtually free of side effects and 
toxicity (clinically) on such dosage. 
 
I. Introduction 
Allergic rhinitis is commonly found in Kashmir. Generally found in Atopic individuals, it implies a 
familial tendency to manifest alone or in combination of such conditions like, Asthma, urticarial and eczematous 
dermatitis (1, 2). Individuals without familial tendency can also develop hypersensitive reactions, associated 
with same class of Antibody (IgE) (3). Thus designates the diseases of immediate type of hypersensitivity. H1-
Antagonist have been widely used for the treatment of rhinitis for nearly 50 years(4, 5). Prophylactic 
Fexofenadine, a non-sedating, highly selective antagonist shows more promising activity with mild side effects 
at proper dosage schedule (6-10). This paper reports the results of a clinical trial ofFexofenadine as prophylactic 
treatment in allergic rhinitis. 
 
II. Materials And Methods 
10 Patients (7 males and 3 females)were followed for one and half year. Each patient has a routine 
clinical evaluation and investigation like CBC, TLC, DLC, Stool test, ECG all leads (11), X-ray  PNS view, in 
few NCCT PNS, Trans- illumination test and procedures like Antral proof puncture and postural test (12, 13). 
Majority of the patients were adults and the age varied between 18 to 30 years.  
The patients presented with nasal discharge/obstruction, sneezing (10 or more times at a time) 
facial/referred pains, itching of nose, eyes, palate and pharynx were kept in the category of patients suffering  
from Seasonal Allergic Rhinitis (so noted on history about particular month) (14-16). These subjects were 
advised to take the drug 120 mg once daily in the morning before the initial noted symptoms along with all 
preventive measures for the whole season.  
The patients presented with Perennial Allergic Rhinitiswere subjected to take the drug 120 mg at bed 
time i.e.  24 hourly for 3 weeks with 1 week drug washout interval in a month for one year there after the drug 
was given at 48 hourly for 3 weeks again with 1week drug washout for 3 months and with time the dose were 








Table 1: Symptomatology of the group 
Symptoms No. of cases 
Nasal obstruction(functional/ mechanical) 10 
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The Table 1 shows nasal obstruction (functional) in almost 100% cases, rhinorrhea in 90% of cases, 
sneezing in 70% and chronic sinusitis symptoms in 30-60% of cases. The characteristic episodic mucoid 
secretion followed by muco-purulent discharge resulted in chronic sinusitis especially of maxillary sinus. 
Hypertrophy of the turbinate’s and obstruction of the Sinus Ostia and Eustachian tubes precipitates secondary 
infections of the sinus and middle ear. It has been observed that patients suffering from allergic rhinitis gets 
recurrent bacterial infection thus relieves them for a period probably due to Eosinopenia (18). At the same time 
muco-purulent discharge coats the nasal mucosa and prevents the allergen to come in to contact with mucosa. 
The affected persons uncommonly suffers from Rhino-viral infection reasons seemed to me increased 
temperature of the nasal mucosa (Rhino virus grows at 33-34 centigrade temperature and at a PH greater or 
equal to3) (3, 19, 20).  
It has been observed that acute illness are not controlled by 2
nd
 generation, non-sedating 
antagonists(21).  Out of 10 cases, 4 were having seasonal allergic rhinitis who were symptomatically better after 
prophylactic Fexofenadine 120 mg once daily were given as per dates of pollination.  
Out of 6 cases of Perennial allergic rhinitis 1 patient underwent Septoplasty, 1 patient underwent 
polypectomy, 1 was in need of repeated antral washes of maxillary sinus, 3 patients presents with recurrent 










Most of the side-effects goes off with time, as shown in table no 3. 
Therefore the drug were useful in prophylactic therapy. 
 
Table no. 3 shows the clinically noted side-effects of the drug. 
Side Effects No. of cases 
Headache 8. 
G.I. upset(loose motion) 6. 
Rebound nasal congestion 5. 
Dryness of nasal mucosa 3. 
Dryness of mucosa of pharynx 2. 
Polymorphic ventricular tachycardia Nil 
 
Discussion 
H1-Receptor antagonists, widely used for the last 50 years were introduced in the late 1930’s (22). 
Fexofenadine, one of the most selective H1-antigonist, non-sedative having no H2, anti 5-HT or anti adrenergic 
properties. 
 
Antagonist Max(hrs): T  1/2: Wheal suppression (hrs.) (23) 
Fexofenadine 1.0 11-16 hrs 12-24 hrs. 
 
It is well-absorbed from G.I.T, excretion occurs equally in urine and feces. Since it’s minimally 
metabolized no interaction with CYP3A4 inhibition has be reported (24).Its largely free of arrhythmogenic 
potential, but with pre-existing long QT interval patients medicine shall be given with caution (25). 
Fexofenadine exerts maximal benefit if taken before an anticipated allergic reaction, so that the antagonist may 
occupy the receptors before the agonist (histamine) is released (20). The dosage has been selected and adjusted 
from time to time as drug gets accumulated in the body, thus requires wash-out intervals. The dose of 120 mg 
daily has been recommended (FDA).We select dose 120 mg 24 hrly i.e. from 8 am. to 8 am initially to be 
continued for 3 weeks with an interval of 1 week free drug (20). As patients were symptomatically better the 
drug were given at 48 hrly with wash-out interval of 1 week and with time the dose were reduced to 60 mg at 72 
Rhinorrhea /discharge. 9 
Sneezing. 7 
Redness/lacrimation of eyes. 4 
Urticaria/angioedema/asthma. 2 
PAR with Symptoms relieved 
Chronic on acute sinusitis. 95% 
Post-operation,  Septoplasty 
polypectomy 
80% 
Following Antral washes. 65% 
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hrly .It is observed that with age the intensity of the allergic manifestation diminishes (3). Experiments have 
demonstrated that Fexofenadine from 0.20-5 µ mol/L had no significant effect; While  as parent Terfenadine 1 µ 
mol/L markedly reduces the potassium currents(IK) in ventricular myocytes(26),causes excessive delay in 
cardiac repolarization leads to a condition Torsades de pointes(27-30). Above all, every patient were questioned 
after every week for any disturbances ,headaches, palpitations, dizziness, shortness of breath or any G.I .upset 
etc. Every patient were advised not to take medicines without consultation especially Antibiotics, Antifungals 
etc. Thereby Fexofenadine monotherpy were well tolerated in our patients. And the side-effects observed were 
mild and transitory. The drug may be considered very useful in the treatment of Allergic Rhinitis i.e. 
PROPHYLACTICALLY. 
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